Cargando…
Injectable Nano Drug Delivery Systems for the Treatment of Breast Cancer
Breast cancer is the most diagnosed type of cancer, with 2.26 million cases and 685,000 deaths recorded in 2020. If left untreated, this deadly disease can metastasize to distant organs, which is the reason behind its incurability and related deaths. Currently, conventional therapies are used to tre...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785637/ https://www.ncbi.nlm.nih.gov/pubmed/36559276 http://dx.doi.org/10.3390/pharmaceutics14122783 |
_version_ | 1784858097114677248 |
---|---|
author | Kafle, Urmila Agrawal, Satish Dash, Alekha K. |
author_facet | Kafle, Urmila Agrawal, Satish Dash, Alekha K. |
author_sort | Kafle, Urmila |
collection | PubMed |
description | Breast cancer is the most diagnosed type of cancer, with 2.26 million cases and 685,000 deaths recorded in 2020. If left untreated, this deadly disease can metastasize to distant organs, which is the reason behind its incurability and related deaths. Currently, conventional therapies are used to treat breast cancer, but they have numerous shortcomings such as low bioavailability, short circulation time, and off-target toxicity. To address these challenges, nanomedicines are preferred and are being extensively investigated for breast cancer treatment. Nanomedicines are novel drug delivery systems that can improve drug stability, aqueous solubility, blood circulation time, controlled release, and targeted delivery at the tumoral site and enhance therapeutic safety and effectiveness. Nanoparticles (NPs) can be administered through different routes. Although the injectable route is less preferred than the oral route for drug administration, it has its advantages: it helps tailor drugs with targeted moiety, boosts payload, avoids first-pass metabolism, and improves the pharmacokinetic parameters of the active pharmaceutical ingredients. Targeted delivery of nanomedicine, closer to organelles such as the mitochondria and nuclei in breast cancer, reduces the dosage requirements and the toxic effects of chemotherapeutics. This review aims to provide the current status of the recent advances in various injectable nanomedicines for targeted treatment of breast cancer. |
format | Online Article Text |
id | pubmed-9785637 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97856372022-12-24 Injectable Nano Drug Delivery Systems for the Treatment of Breast Cancer Kafle, Urmila Agrawal, Satish Dash, Alekha K. Pharmaceutics Review Breast cancer is the most diagnosed type of cancer, with 2.26 million cases and 685,000 deaths recorded in 2020. If left untreated, this deadly disease can metastasize to distant organs, which is the reason behind its incurability and related deaths. Currently, conventional therapies are used to treat breast cancer, but they have numerous shortcomings such as low bioavailability, short circulation time, and off-target toxicity. To address these challenges, nanomedicines are preferred and are being extensively investigated for breast cancer treatment. Nanomedicines are novel drug delivery systems that can improve drug stability, aqueous solubility, blood circulation time, controlled release, and targeted delivery at the tumoral site and enhance therapeutic safety and effectiveness. Nanoparticles (NPs) can be administered through different routes. Although the injectable route is less preferred than the oral route for drug administration, it has its advantages: it helps tailor drugs with targeted moiety, boosts payload, avoids first-pass metabolism, and improves the pharmacokinetic parameters of the active pharmaceutical ingredients. Targeted delivery of nanomedicine, closer to organelles such as the mitochondria and nuclei in breast cancer, reduces the dosage requirements and the toxic effects of chemotherapeutics. This review aims to provide the current status of the recent advances in various injectable nanomedicines for targeted treatment of breast cancer. MDPI 2022-12-13 /pmc/articles/PMC9785637/ /pubmed/36559276 http://dx.doi.org/10.3390/pharmaceutics14122783 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kafle, Urmila Agrawal, Satish Dash, Alekha K. Injectable Nano Drug Delivery Systems for the Treatment of Breast Cancer |
title | Injectable Nano Drug Delivery Systems for the Treatment of Breast Cancer |
title_full | Injectable Nano Drug Delivery Systems for the Treatment of Breast Cancer |
title_fullStr | Injectable Nano Drug Delivery Systems for the Treatment of Breast Cancer |
title_full_unstemmed | Injectable Nano Drug Delivery Systems for the Treatment of Breast Cancer |
title_short | Injectable Nano Drug Delivery Systems for the Treatment of Breast Cancer |
title_sort | injectable nano drug delivery systems for the treatment of breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785637/ https://www.ncbi.nlm.nih.gov/pubmed/36559276 http://dx.doi.org/10.3390/pharmaceutics14122783 |
work_keys_str_mv | AT kafleurmila injectablenanodrugdeliverysystemsforthetreatmentofbreastcancer AT agrawalsatish injectablenanodrugdeliverysystemsforthetreatmentofbreastcancer AT dashalekhak injectablenanodrugdeliverysystemsforthetreatmentofbreastcancer |